EIT Health adds four Partners as seven other Partners upgrade to Core status

Effective 1 January

EIT Health continued to grow in size, while seeing increased commitment to its partnership, as of 1 January 2019, when four new Partners joined our network and seven existing Partners upgraded their status from Associate Partner to Core Partner.

The new partnerships and upgrades were approved by the Supervisory Board in the end of last year. EIT Health exists through partnership. Our Partners cooperate with one another in the many activities that we undertake to promote healthcare innovation.

EIT Health leverages the expertise of more than 140 leading organisations spanning key areas of healthcare, such as pharma, medtech, payers, research institutions and universities. Connecting our Partners’ knowledge and competence, we accelerate collaborations in cutting-edge projects, develop health education for the future and speed up new business development.

New Partners

As of 1 January 2019, the following new partners have been added:

• City of Rotterdam, Associate, Belgium/Netherlands: The second-largest city in the Netherlands with a robust innovation ecosystem.
• Colruyt Group, Core, Belgium/Netherlands: Colruyt offers numerous retail chains, own brands and activities, including Newpharma, the largest online pharmacy in Belgium.
• Lode Holding, Associate, Belgium/Netherlands: With a rich experience, history and a wide range of products and services in life sciences, Lode Holding seeks to contribute to medical technology, healthcare and a healthy environment.
• University of Luxembourg & LCSB, Associate, Belgium/Netherlands: Founded in 2003, the University of Luxembourg is the only public university of the Grand Duchy of Luxembourg. The LCSB, founded in 2009, seeks to accelerate biomedical research by closing the link between systems biology and medical research. The LCSB focuses on the study of neurodegenerative diseases, with an emphasis on Parkinson’s disease.

Upgrading to Core Partners

As of 1 January 2019, the following EIT Health Partners have upgraded their status, from Associate Partners to Core Partners.

• Altran, France: A world leader in engineering and R&D with a large life-sciences division.
• Danish Technical University, Scandinavia: DTU focuses on engineering sciences and technology and is renowned for its business-orientation in research and education. DTU is a leader in innovation and offers a strong profile within all stages of the innovation chain on campus.
• ETH Zurich, Germany: One of the leading international universities for technology and the natural sciences. It is well known for its excellent education and ground-breaking fundamental research – and for implementing its results directly into practice.
• Janssen, Germany: Janssen comprises the pharmaceutical companies of Johnson & Johnson. With more than 30,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases, they collaborate with the world for the health of everyone in it. As part of the Johnson & Johnson family of companies, they can leverage not only expertise in new drug discovery and development but they are also well connected with medical devices, diagnostics and consumer business.
• TU Delft, Belgium/Netherlands: TU Delft is the largest Dutch University of Technology offering a wide range of design, engineering and sciences education programmes and research disciplines. Many of these programmes and disciplines focus their application in health.
• UMCG, Belgium/Netherlands: The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). Research and education at the UMCG are funded through the University of Groningen, and the Faculty of Medical Sciences functions as an integral part of the University.
• University of Tartu, Scandinavia: The Estonian Genome Center at the University of Tartu is a population-based biobank, consisting of samples and rich eHealth data (from national registers) of 52 000 gene donors with genomics core-facility and strong competence in genomics, metabolomics etc.